COMMUNIQUÉS West-GlobeNewswire

-
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025 -
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
02/01/2025 -
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025 -
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
02/01/2025 -
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
02/01/2025 -
BioStem Technologies CEO to Present at Biotech Showcase 2025
02/01/2025 -
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
02/01/2025 -
The Ensign Group Closes on Expansion in Tennessee, Adds Its First Operation in Alabama
02/01/2025 -
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
02/01/2025 -
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
02/01/2025 -
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
01/01/2025 -
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
31/12/2024 -
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
31/12/2024 -
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
31/12/2024 -
Firefly Neuroscience Closes on Financing of up to $12.4 Million
31/12/2024 -
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31/12/2024 -
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
31/12/2024 -
Vireo Growth Inc. Announces Closing of Oversubscribed US$81 Million Equity Securities Offering
31/12/2024 -
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
31/12/2024
Pages